You might also like
The Cigna Group is a global health company that operates through two main growth platforms: Evernorth Health Services and Cigna Healthcare. The company provides pharmacy benefits, specialty pharmacy, specialty distribution, and care delivery and management solutions through Evernorth Health Services, partnering with various stakeholders such as health plans and healthcare providers . Cigna Healthcare offers comprehensive medical and coordinated solutions, including commercial medical plans and international healthcare solutions, making it a foundational growth business for the company . Additionally, Cigna's business activities include Other Operations, which encompass corporate-owned life insurance and run-off businesses, although these contribute less significantly to overall revenue .
- Evernorth Health Services - Focuses on pharmacy benefits, specialty pharmacy, specialty distribution, and care delivery and management solutions, partnering with health plans, employers, governmental organizations, and healthcare providers.
- Pharmacy Benefit Services - Provides pharmacy benefits management services.
- Specialty and Care Services - Offers specialty pharmacy and care management solutions.
- Cigna Healthcare - Provides comprehensive medical and coordinated solutions through its U.S. Healthcare and International Health operating segments.
- U.S. Healthcare - Offers commercial medical plans, Medicare Advantage, Medicare Supplement, and individual health insurance plans.
- International Health - Provides healthcare solutions in international markets.
- Other Operations - Includes corporate-owned life insurance and run-off businesses, contributing less significantly to overall revenue.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David M. Cordani ExecutiveBoard | Chairman and Chief Executive Officer | Board Member at General Mills, Inc.; Executive Committee Member of AHIP; Chairman of the U.S. Chamber of Commerce’s U.S.-Korea Business Council | Joined CI in 1991; CEO since 2009; Chairman since January 2022; led CI to become a Fortune 15 company; co-authored a best-selling book. | View Report → |
Brian C. Evanko Executive | Executive Vice President, Chief Financial Officer, and President and CEO of Cigna Healthcare | N/A | Serving as EVP, CFO, and CEO of Cigna Healthcare; confirmed by 8-K filing dated January 30, 2025. | |
Eric P. Palmer Executive | Executive Vice President, Enterprise Strategy, and President and CEO of Evernorth Health Services | N/A | Serving in current role since February 5, 2024; compensation adjusted for expanded responsibilities. | |
Jamie Kates Executive | Chief Accounting Officer | N/A | Chief Accounting Officer since July 1, 2024; with CI since 2009; CPA with extensive accounting and compliance experience. | |
Nicole S. Jones Executive | Executive Vice President, Chief Administrative Officer, and General Counsel | N/A | Joined CI in 2006; expanded role in September 2023 to include Chief Administrative Officer responsibilities. | |
Noelle K. Eder Executive | Executive Vice President, Global Chief Information Officer | N/A | Joined CI in September 2020; expanded role in September 2023 to lead Technology and Operations. | |
Donna F. Zarcone Board | Director | CDW Corporation (Audit Committee, Nominating & Corporate Governance Committee); Quinnox (Chair of the Audit Committee); Duchossois Group (Chair of the Investment Committee); Smithsonian Institution (Vice Chair of the National Board) | Director since 2005; extensive experience in corporate governance and audit expertise. | |
Elder Granger, M.D. Board | Director | President and CEO of THE 5Ps, LLC; Board Member at Better Therapeutics, Inc. and DLH Holdings Corporation | Director since 2018; retired U.S. Army Major General; extensive healthcare management experience. | |
Eric C. Wiseman Board | Lead Independent Director | Board of Trustees, Wake Forest University; Board of Visitors, Wake Forest School of Business; American Heart Association CEO Roundtable | Director since 2007; Lead Independent Director since January 2022; extensive risk management experience. | |
Eric J. Foss Board | Director | Director at Primo Water Corporation; Non-Executive Chair at Selina Hospitality PLC; National Board Member for the Back on My Feet Foundation | Director since 2011; former CEO of Aramark and The Pepsi Bottling Group; led IPOs for both companies. | |
George Kurian Board | Director | CEO of NetApp, Inc.; Board Member at NetApp, Inc. | Director since 2021; CEO of NetApp; extensive experience in technology innovation and strategic leadership. | |
Kathleen M. Mazzarella Board | Director | Core & Main (Audit Committee); Waste Management, Inc. (Non-Executive Chair); Concordance First Chance Campaign (Co-Chair); Greater St. Louis, Inc. (Board Member) | Director since 2018; Chair, President, and CEO of Graybar Electric Company; first woman to lead Graybar since 1925. | |
Kimberly A. Ross Board | Director | Nestlé S.A. (Audit Committee); University of South Florida (Foundation Board, Advisory Board of the Muma College of Business) | Director since 2020; extensive experience in corporate finance and strategy; former CFO of WeWork and Baker Hughes. | |
Mark B. McClellan, M.D., Ph.D. Board | Director | Director at Duke-Robert J. Margolis, M.D., Center for Health Policy; Board Member at Alignment Healthcare, Inc. and Johnson & Johnson | Director since 2018; former FDA Commissioner and CMS Administrator; extensive public service and leadership experience. | |
Neesha Hathi Board | Director | Advisory Board of the Morrison Center for Marketing & Data Analytics at UCLA; The Charles Schwab Foundation | Director since 2021; Head of Wealth and Advice Solutions at Charles Schwab; recognized as a transformative leader in financial services. | |
William J. DeLaney Board | Director | Director at Union Pacific Corporation (Audit Committee, Compensation and Benefits Committee) | Director since 2018; extensive experience in financial operations and strategic planning. |
-
Given the potential for Skyrizi and Rinvoq to limit the adoption of HUMIRA biosimilars, how does Cigna plan to ensure the success of its biosimilar offerings and mitigate the risk of losing market share in this space?
-
With the Inflation Reduction Act causing increases in Medicare Part D premiums and potential disruptions, how is Cigna adjusting its strategy to manage these changes, and what impact do you anticipate on your Evernorth and Express Scripts businesses?
-
As GLP-1 drugs become a major driver of pharmacy benefit trends, how is Cigna addressing the affordability challenges for clients and patients, and how do you foresee this affecting the adoption and effectiveness of your EnCircleRx program?
-
Considering the current scrutiny and regulatory pressures on pharmacy benefit managers regarding pricing transparency and payment models, how is Cigna evolving its PBM business to address these concerns while maintaining profitability?
-
Given the anticipated rise of Individual Coverage Health Reimbursement Arrangements (ICRAs) and their potential to disrupt the small group market, what is Cigna's strategy to mitigate any financial impact and capitalize on opportunities within the individual exchange business?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MDLIVE, Inc. | 2021 | Cigna fully acquired MDLIVE, Inc. on April 19, 2021, for $2.0 billion financed through cash on hand and commercial paper borrowings, consolidating its prior 97% stake to 100% ownership. The acquisition brought significant intangible assets—including customer relationships, internal-use software, and provider networks—to expand Cigna's Evernorth segment into virtual care and alternative care models, though MDLIVE’s financials were not material to Cigna's overall results in 2021. |
Recent press releases and 8-K filings for CI.
- Cigna Group has completed the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC), streamlining its portfolio.
- The proceeds from the sale are primarily expected to fund share repurchases as part of its capital deployment priorities.
- Cigna will continue offering pharmacy benefit services and related solutions through its Evernorth Health Services under service agreements with HCSC.
- Cigna Group has successfully completed the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC) as announced on March 19, 2025.
- Proceeds from the transaction are expected to be used in line with the company’s capital deployment priorities, with the majority earmarked for share repurchases.
- The company will continue to provide pharmacy benefit services and other solutions to the Medicare businesses through Evernorth Health Services under post-closing service agreements with HCSC.
- Brian Evanko is named President and Chief Operating Officer effective March 31, following his prior role as President and CEO for Cigna Healthcare and as CFO since 2021.
- Ann Dennison is appointed as Executive Vice President and Chief Financial Officer, adding to the company’s strategic leadership team.
- Nicole Jones will expand her responsibilities by taking on oversight of Enterprise Marketing, while Eric Palmer, CEO of Evernorth Health Services, departs at the end of April.
- The company reaffirms its full-year 2025 financial outlook with consolidated adjusted income from operations expected to be at least $29.50 per share.
- Leadership Update: Cigna Group announced key management changes effective March 31, 2025, with Brian C. Evanko appointed as President and Chief Operating Officer and Ann M. Dennison as Executive Vice President and Chief Financial Officer.
- Compensation Details: As part of these changes, Mr. Evanko’s base salary is set at $1,100,000 with additional incentive targets, while Ms. Dennison’s base salary is $800,000, including an approved transitional strategic performance share grant.
- Guidance Reaffirmation: The company reaffirmed its full year 2025 outlook with projected consolidated adjusted income from operations of at least $29.50 per share, along with segment targets of $7.2 billion pre-tax adjusted income for Evernorth and $4.1 billion for Cigna Healthcare.
- Cigna Group’s senior management detailed challenges in the stop-loss business and structural shifts driven by rising specialty drug costs, which impacted 2024 performance and informed their 2025 outlook.
- The company is updating its pricing assumptions for stop-loss renewals, with later 2025 and 2026 pricing expected to better reflect current cost pressures.
- Strong cash flow generation is highlighted, with expectations of over $10 billion in operating cash flow and a share repurchase program exceeding $1 billion year-to-date, supporting balanced capital deployment including potential bolt-on M&A.
- Evernorth’s growth initiatives, including expanded biosimilar adoption and GLP-1 cost guarantee programs, are key components of Cigna’s broader strategy moving forward.